Rigel Pharmaceuticals, Inc. (RIGL)
Oxford Ledge is still expanding full research coverage of RIGL. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Biotechnology company commercializing three FDA-approved therapies for blood cancers and related disorders while advancing pipeline programs in collaboration with academic and pharmaceutical partners.
SEC filings
- 8-K Departure/election of directors or officers; Shareholder vote results 2026-05-20
- 8-K Entry into material agreement 2026-05-12
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-05
- 10-Q Quarterly financial report (unaudited) 2026-05-05
- 8-K Termination of material agreement 2026-04-21
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for RIGL. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open RIGL in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.